Email Alert RSS
Volume 14 Issue 1
Jan.  2023
Turn off MathJax
Article Contents
Abstract
References
LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
Citation: LI Yi, XU Yingchun. A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(1): 9-17. DOI: 10.12290/xhyxzz.2022-0697
shu

A New Chapter in the COVID-19 Pandemic: the Characteristics of Omicron Variant and A New Step for Scientific Epidemic Prevention and Control

  • 1.

    Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 3.

    Graduate School, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-074

Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences 2021-I2M-1-038

Beijing Key Clinical Specialty for Laboratory Medicine -Excellent Project 2K201000

More Information
  • Corresponding author:

    XU Yingchun, E-mail: xycpumch@139.com

  • Received Date: December 05, 2022
  • Accepted Date: December 19, 2022
  • Available Online: December 25, 2022
  • Issue Publish Date: January 29, 2023
    Graphical Abstract
    • Abstract
  • Since the outbreak of COVID-19, SARS-CoV-2 has continued to evolve. As the fifth variants of concern (VOCs) announced by the World Health Organization, Omicron has significantly changed from previous VOCs in terms of genome, biological and epidemiological characteristics. Although the severe illness and mortality caused by Omicron infection are significantly lower than those caused by the previous VOCs, Omicron's strong transmission ability has continued to break through the epidemic prevention barrier and human immunity barrier established by prior infections and vaccines. Omicron has opened a new chapter in the COVID-19 pandemic. In this paper, we review the changes in genome and biological characteristics of Omicron and its subspecies as well as the differences in epidemiological characteristics between Omicron and influenza viruses in order to provide scientific basis for the optimization of epidemic prevention and control.
    • FullText(HTML)
    • References (67)
  • [1]
    World Health Organization. SARS-CoV-2 variants of concern and variants of interest[EB/OL]. [2022-12-06]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/.
    [2]
    Berkhout B, Herrera-Carrillo E. SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant[J]. J Virol, 2022, 96: e0009022. DOI: 10.1128/jvi.00090-22
    [3]
    Dejnirattisai W, Huo J, Zhou D, et al. SARS-CoV-2 Omicron-B. 1.1.529 leads to widespread escape from neutralizing antibody responses[J]. Cell, 2022, 185: 467-484. e15. DOI: 10.1016/j.cell.2021.12.046
    [4]
    Chen J, Wang R, Gilby NB, et al. Omicron Variant (B. 1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance[J]. J Chem Inf Model, 2022, 62: 412-422. DOI: 10.1021/acs.jcim.1c01451
    [5]
    Mannar D, Saville JW, Zhu X, et al. SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein-ACE2 complex[J]. Science, 2022, 375: 760-764. DOI: 10.1126/science.abn7760
    [6]
    Tegally H, Moir M, Everatt J, et al. Emergence of SARS-CoV-2 Omicron lineages BA. 4 and BA. 5 in South Africa[J]. Nat Med, 2022, 28: 1785-1790. DOI: 10.1038/s41591-022-01911-2
    [7]
    World Health Organization. Weekly epidemiological update on Covid-19-23 November 2022[EB/OL]. (2022-11-23)[2022-12-06] https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-23-nove-mber-2022.
    [8]
    Hadfield J, Megill C, Bell SM, et al. Nextstrain: real-time tracking of pathogen evolution[J]. Bioinformatics, 2018, 34: 4121-4123. DOI: 10.1093/bioinformatics/bty407
    [9]
    Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization[J]. Nature, 2022, 602: 671-675. DOI: 10.1038/s41586-021-04389-z
    [10]
    Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes?[J]. Nat Rev Microbiol, 2022, 20: 187-188. DOI: 10.1038/s41579-022-00708-x
    [11]
    Wilks SH, Mühlemann B, Shen X, et al. Mapping SARS-CoV-2 antigenic relationships and serological responses[J]. bioRxiv, 2022. doi: 10.1101/2022.01.28.477987.
    [12]
    Thakur V, Ratho RK. OMICRON (B. 1.1.529): A new SARS-CoV-2 variant of concern mounting worldwide fear[J]. J Med Virol, 2022, 94: 1821-1824. DOI: 10.1002/jmv.27541
    [13]
    Menni C, Valdes AM, Polidori L, et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observa-tional study from the ZOE COVID Study[J]. Lancet, 2022, 399: 1618-1624. DOI: 10.1016/S0140-6736(22)00327-0
    [14]
    Kim MK, Lee B, Choi YY, et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea[J]. J Korean Med Sci, 2022, 37: e31. DOI: 10.3346/jkms.2022.37.e31
    [15]
    Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study[J]. Lancet, 2022, 399: 437-446. DOI: 10.1016/S0140-6736(22)00017-4
    [16]
    Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B. 1.1.529) variant and BA. 1/BA. 1.1 or BA. 2 subvariant infection in Southern California[J]. Nat Med, 2022, 28: 1933-1943. DOI: 10.1038/s41591-022-01887-z
    [17]
    Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study[J]. Lancet Glob Health, 2022, 10: e961-e969. DOI: 10.1016/S2214-109X(22)00114-0
    [18]
    World Health Organization. Severity of disease associated with Omicron variant as compared with Delta variant in hospitalized patients with suspected or confirmed SARS-CoV-2 infection[EB/OL]. (2022-06-07)[2022-12-06]. https://www.who.int/publications/i/item/9789240051829.
    [19]
    Ulloa AC, Buchan SA, Daneman N, et al. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada[J]. JAMA, 2022, 327: 1286-1288. DOI: 10.1001/jama.2022.2274
    [20]
    Strasser ZH, Greifer N, Hadavand A, et al. Estimates of SARS-CoV-2 Omicron BA. 2 Subvariant Severity in New England[J]. JAMA Netw Open, 2022, 5: e2238354. DOI: 10.1001/jamanetworkopen.2022.38354
    [21]
    Davies MA, Morden E, Rosseau P, et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA. 4 and BA. 5 compared with previous waves in the Western Cape Province, South Africa[J]. Int J Infect Dis, 2022. doi: 10.1101/2022.06.28.22276983.
    [22]
    Callaway E. What Omicron's BA. 4 and BA. 5 variants mean for the pandemic[J]. Nature, 2022, 606: 848-849. DOI: 10.1038/d41586-022-01730-y
    [23]
    Bentley EG, Kirby A, Sharma P, et al. SARS-CoV-2 Omicron-B. 1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19[J]. bioRxiv, 2021. doi: https://doi.org/10.1101/2021.12.26.474085.
    [24]
    Hui KPY, Ho JCW, Cheung MC, et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo[J]. Nature, 2022, 603: 715-720. DOI: 10.1038/s41586-022-04479-6
    [25]
    Brüssow H. COVID-19: Omicron-the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2[J]. Microb Biotechnol, 2022, 15: 1927-1939. DOI: 10.1111/1751-7915.14064
    [26]
    Peacock TP, Brown JC, Zhou J, et al. The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein[J]. bioRxiv, 2022: 2021.12.31.474653.
    [27]
    Meng B, Abdullahi A, Ferreira I, et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity[J]. Nature, 2022, 603: 706-714. DOI: 10.1038/s41586-022-04474-x
    [28]
    Goga A, Bekker LG, Garrett N, et al. Breakthrough Covid-19 infections during periods of circulating Beta, Delta and Omicron variants of concern, among health care workers in the Sisonke Ad26. COV2. S vaccine trial, South Africa[J]. medRxiv, 2021: 2021.12.21.21268171.
    [29]
    Altarawneh HN, Chemaitelly H, Hasan MR, et al. Protection against the Omicron Variant from Previous SARS-CoV-2 Infection[J]. N Engl J Med, 2022, 386: 1288-1290. DOI: 10.1056/NEJMc2200133
    [30]
    Khan K, Karim F, Ganga Y, et al. Omicron BA. 4/BA. 5 escape neutralizing immunity elicited by BA. 1 infection[J]. Nat Commun, 2022, 13: 4686. DOI: 10.1038/s41467-022-32396-9
    [31]
    Ohashi H, Hishiki T, Akazawa D, et al. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA. 1 and BA. 2[J]. Antiviral Res, 2022, 205: 105372. DOI: 10.1016/j.antiviral.2022.105372
    [32]
    Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA. 2[J]. N Engl J Med, 2022, 386: 1475-1477. DOI: 10.1056/NEJMc2201933
    [33]
    Wang Q, Guo Y, Iketani S, et al. Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12.1, BA. 4 and BA. 5[J]. Nature, 2022, 608: 603-608.
    [34]
    Yu J, Collier AY, Rowe M, et al. Neutralization of the SARS-CoV-2 Omicron BA. 1 and BA. 2 Variants[J]. N Engl J Med, 2022, 386: 1579-1580. DOI: 10.1056/NEJMc2201849
    [35]
    Kurhade C, Zou J, Xia H, et al. Neutralization of Omicron BA. 1, BA. 2, and BA. 3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine[J]. Nat Commun, 2022, 13: 3602. DOI: 10.1038/s41467-022-30681-1
    [36]
    Chemaitelly H, Abu-Raddad LJ. Waning effectiveness of COVID-19 vaccines[J]. Lancet, 2022, 399: 771-773. DOI: 10.1016/S0140-6736(22)00277-X
    [37]
    Hachmann NP, Miller J, Collier AY, et al. Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA. 2.12.1, BA. 4, and BA. 5[J]. N Engl J Med, 2022, 387: 86-88. DOI: 10.1056/NEJMc2206576
    [38]
    Tuekprakhon A, Nutalai R, Dijokaite-Guraliuc A, et al. Antibody escape of SARS-CoV-2 Omicron BA. 4 and BA. 5 from vaccine and BA. 1 serum[J]. Cell, 2022, 185: 2422-2433. e13. DOI: 10.1016/j.cell.2022.06.005
    [39]
    Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic[J]. Lancet, 2021, 398: 2126-2128. DOI: 10.1016/S0140-6736(21)02758-6
    [40]
    Redd AD, Nardin A, Kared H, et al. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8(+) T-Cell Epitopes Identified in COVID-19 Convalescent Individuals[J]. mBio, 2022, 13: e0361721. DOI: 10.1128/mbio.03617-21
    [41]
    Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19[J]. Nat Med, 2020, 26: 842-844. DOI: 10.1038/s41591-020-0901-9
    [42]
    Liu J, Chandrashekar A, Sellers D, et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron[J]. Nature, 2022, 603: 493-496. DOI: 10.1038/s41586-022-04465-y
    [43]
    Tarke A, Coelho CH, Zhang Z, et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron[J]. Cell, 2022, 185: 847-859. e11. DOI: 10.1016/j.cell.2022.01.015
    [44]
    Kirsebom FCM, Andrews N, Stowe J, et al. COVID-19 vaccine effectiveness against the omicron (BA. 2) variant in England[J]. Lancet Infect Dis, 2022, 22: 931-933. DOI: 10.1016/S1473-3099(22)00309-7
    [45]
    Cheung PH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022[J]. Emerg Microbes Infect, 2022, 11: 1072-1078. DOI: 10.1080/22221751.2022.2060137
    [46]
    Ministry of Health, Singapore. COVID-19 Statistics[EB/OL]. [2022-12-06]. https://www.moh.gov.sg/COVID-19/statistics.
    [47]
    McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study[J]. Lancet Infect Dis, 2022, 22: 1435-1443. DOI: 10.1016/S1473-3099(22)00345-0
    [48]
    Xu H, Li H, You H, et al. Effectiveness of inactivated COVID-19 vaccines against mild disease, pneumonia, and severe disease among persons infected with SARS-CoV-2 Omicron variant: Real-world study in Jilin Province, China[J]. Emerg Microbes Infect, 2022: 1-30.
    [49]
    Zhang X, Zhang W, Chen S. Shanghai's life-saving efforts against the current omicron wave of the COVID-19 pandemic[J]. Lancet, 2022, 399: 2011-2012. DOI: 10.1016/S0140-6736(22)00838-8
    [50]
    Domingo FR, Waddell LA, Cheung AM, et al. Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review[J]. medRxiv, 2021: 2021.06.03.21258317.
    [51]
    Wulf Hanson S, Abbafati C, Aerts JG, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021[J]. JAMA, 2022, 328: 1604-1615. DOI: 10.1001/jama.2022.18931
    [52]
    Hastie CE, Lowe DJ, McAuley A, et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study[J]. Nat Commun, 2022, 13: 5663. DOI: 10.1038/s41467-022-33415-5
    [53]
    Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study[J]. Lancet Infect Dis, 2022, 22: 43-55. DOI: 10.1016/S1473-3099(21)00460-6
    [54]
    Ayoubkhani D, Bermingham C, Pouwels KB, et al. Trajectory of long covid symptoms after COVID-19 vaccination: community based cohort study[J]. Bmj, 2022, 377: e069676.
    [55]
    Antonelli M, Pujol JC, Spector TD, et al. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2[J]. Lancet, 2022, 399: 2263-2264. DOI: 10.1016/S0140-6736(22)00941-2
    [56]
    Faust JS, Del Rio C. Assessment of Deaths From COVID-19 and From Seasonal Influenza[J]. JAMA Intern Med, 2020, 180: 1045-1046. DOI: 10.1001/jamainternmed.2020.2306
    [57]
    Ludwig M, Jacob J, Basedow F, et al. Clinical outcomes and characteristics of patients hospitalized for Influenza or COVID-19 in Germany[J]. Int J Infect Dis, 2021, 103: 316-322. DOI: 10.1016/j.ijid.2020.11.204
    [58]
    Xue L, Jing S, Zhang K, et al. Infectivity versus fatality of SARS-CoV-2 mutations and influenza[J]. Int J Infect Dis, 2022, 121: 195-202. DOI: 10.1016/j.ijid.2022.05.031
    [59]
    Jay Hilotin, Vijith Pulikkal. COVID-19: Omicron now less deadly than flu?[EB/OL]. (2022-3-11)[2022-12-06]. https://gulfnews.com/special-reports/COVID-19-omicron-now-less-deadly-than-flu-1.1647011926766.
    [60]
    Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause Mortality in the US and 20 Comparison Countries, June 2021-March 2022[J]. JAMA, 2022. doi: 10.1001/jama.2022.21795.
    [61]
    Ministry of Health (Singapore). COVID-19 Situation at a Glance[EB/OL]. [2022-12-06] https://www.moh.gov.sg/.
    [62]
    Iuliano AD, Roguski KM, Chang HH, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study[J]. Lancet, 2018, 391: 1285-1300. DOI: 10.1016/S0140-6736(17)33293-2
    [63]
    Li ZJ, Yu LJ, Zhang HY, et al. Broad Impacts of Coronavirus Disease 2019(COVID-19) Pandemic on Acute Respiratory Infections in China: An Observational Study[J]. Clin Infect Dis, 2022, 75: e1054-e1062. DOI: 10.1093/cid/ciab942
    [64]
    Huang WJ, Cheng YH, Tan MJ, et al. Epidemiological and virological surveillance of influenza viruses in China during 2020-2021[J]. Infect Dis Poverty, 2022, 11: 74. DOI: 10.1186/s40249-022-01002-x
    [65]
    Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap?[J]. Infect Dis Now, 2021, 51: 418-423. DOI: 10.1016/j.idnow.2021.05.004
    [66]
    Cai J, Deng X, Yang J, et al. Modeling transmission of SARS-CoV-2 Omicron in China[J]. Nat Med, 2022, 28: 1468-1475. DOI: 10.1038/s41591-022-01855-7
    [67]
    Mallapaty S. Can China avoid a wave of deaths if it lifts strict zero COVID policy?[J]. Nature, 2022, 612: 203. DOI: 10.1038/d41586-022-04235-w
    • Related Articles

  • Cited by

    Periodical cited type(14)

    1. 张海荣，随海田，黄丽芳，周勇. 新型冠状病毒灭活疫苗在不同人群中安全性和有效性研究进展. 中国病毒病杂志. 2024(01): 93-100 .
    2. 桑晓倩，林孟晨，鲍贵栋，吴云峰. 新冠Omicron变异株的人群感染数学模型研究. 中国科技论文在线精品论文. 2024(01): 91-98 .
    3. 赵新通，管健晖，张瑞丰. 基于流固耦合的正压呼吸面罩抗变形分析. 塑料. 2024(02): 135-141 .
    4. 桑晓倩，林孟晨，鲍贵栋，吴云峰. 基于奥密克戎变异株免疫逃逸的新型冠状病毒感染数学模型. 厦门大学学报(自然科学版). 2024(03): 421-430 .
    5. 赵新通，管健晖，张瑞丰. 基于Polyflow正压防护面罩吸塑成型过程. 塑料. 2024(03): 1-6 .
    6. 施卫兴，秦萌，张海兵，袁媛，胡屹，刘清，刘才兄，方颖. 2022年上海市奉贤区新型冠状病毒核酸阳性者再感染风险及影响因素分析. 上海预防医学. 2024(12): 1143-1147 .
    7. 丛晓东，王冰，何沂，范艺龄，袁沙沙，石霞，张子健，苗青. 成人新型冠状病毒奥密克戎感染中医方证应用心得. 北京中医药. 2023(01): 16-18 .
    8. 张喜莲，马融，陈朝远，田雨灵，张盈，李景轩. 儿童新型冠状病毒奥密克戎感染临床证治初探. 北京中医药. 2023(01): 11-15 .
    9. 方辉，张宁，王玉光，郭亚丽，祝勇，刘建. 新型冠状病毒奥密克戎变异株感染重症高危人群症状及中医证候学特征探析. 现代中医临床. 2023(04): 28-33 .
    10. 崔英子，常天瀛，杨薇，仕丽，胡少丹，田琳，孙元枫，王健，王檀，胡灏. 新型冠状病毒肺炎专病库的建设与应用. 长春中医药大学学报. 2023(08): 841-845 .
    11. 姜晓峰，郝慧霞，刘东艳，宋健，迟富利. 内蒙古自治区某口岸城市4起新冠病毒感染疫情的流行特征. 中国国境卫生检疫杂志. 2023(04): 386-391 .
    12. 王文江，张晓璐，仝玉平，赵升. 2023年许昌市新冠病毒分子流行病学特征. 中国国境卫生检疫杂志. 2023(05): 489-492 .
    13. 梅彩霞. 奥密克戎变异株急性感染血液透析患者的临床效应分析. 兵团医学. 2023(03): 40-43 .
    14. 詹广耀，冼柏俊，黄姝贤，黎剑桥，梁君如，廖钊宏. 奥密克戎的感染、免疫及其免疫逃逸机制的研究进展. 广东药科大学学报. 2023(06): 135-142 .

    Other cited types(5)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (673) PDF downloads (227) Cited by(19)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close